Using a Population Pharmacokinetic Model to Estimate the Dosage of Teicoplanin in Patients With Hematologic Malignancy or Critical Illness

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Nov 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to determine the best dosage of a medication called teicoplanin for patients who have serious blood-related cancers or are critically ill. Teicoplanin is used to treat infections caused by certain bacteria, especially when patients have had fevers for more than 48 hours. The goal of the study is to create a model that helps doctors figure out the right amount of teicoplanin needed for each patient, which is important because some patients may respond differently to the medication.

To be eligible for this trial, participants must be adults over 20 years old who are diagnosed with either a hematologic malignancy (like leukemia or lymphoma) or a critical illness. They must also need teicoplanin treatment for a bacterial infection. However, patients who are not facing these specific health issues, those who have received certain treatments recently, or pregnant women are not eligible to participate. If you or a loved one qualifies and chooses to join, you can expect to be part of a study that aims to improve how teicoplanin is used, ultimately leading to better care and outcomes for patients in similar situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients aged over 20 diagnosed with hematologic malignancy or critical illness.
• • Clinically require teicoplanin for treating fever with suspected Gram-positive bacterial infection for more than 48 hours.
• Exclusion Criteria:
• • Adult patients without hematologic malignancy or critical illness.
• • Patients not using teicoplanin for fever with suspected Gram-positive bacterial infection.
• • patients receiving renal dialysis within 48 hours of starting teicoplanin.
• • Patients treated with teicoplanin for less than 48 hours.
• • Pregnant women.